Pharmaust Share Price and Company Fundamentals

0.002 (2.222%)
52 week
0.087 - 0.25

Last traded: Today at 5:39 AM

PharmAust Limited, a clinical-stage company, develops targeted cancer therapeutics for human and animal healthcare. The company develops drug discovery intellectual property for the treatment of various cancers in humans and animals. Its lead candidate is Monepantel, which are in Phase II clinical trials for the treatment of cancer. The company also provides highly specialized medicinal and synthetic chemistry services on a contract basis to clients to the drug discovery and pharmaceutical industries. The company has a research agreement with the Walter and Eliza Hall Institute to investigate the effects of monepantel (MPL) upon human T-lymphotrophic virus-1 (HTLV-1) infections in vitro. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.

Key Metrics

PE ratio


PB ratio


Dividend yield



Market cap


Enterprise value


Company profile

Primary activitiesTo develop its own drug discovery intellectual property as well as providing highly specialised medicinal and synthetic chemistry services on a contract basis to clients.
Industry / SectorBiotechnology / Healthcare
Mailing address5/3 Brodie Hall Drive Bentley WA 6102 Australia
Phone / Fax61 8 9202 6814 / 61 8 9467 6111


Pharmaust does not pay dividends.

Company Executives

As of Jul 2021, following are the company executives and directors listed on Pharmaust.

NameTitleAgeTotal Pay
Dr. Roger Aston B.Sc., BSc (Hons), Ph.D.Exec. Chairman & Acting CEO64284.7k
Mr. Sam Michael Wright A.C.I.S., M.A.I.C.D., AFin, DipAcc, ACIS, MAICDFin. Director, Company Sec. & Director42132.2k
Dr. Richard MollardChief Scientific Officer262.8k
Mr. Robert Charles BishopExec. Director133.59k
Mr. Colin La GaliaChief Exec. Officer of Epichem Pty Ltd187.57k
Ms. Rebecca McCrackanDirector of Epichem Pty Ltd5.91k

Profitability and management effectiveness

Profit margin


Operating margin


Return on assets


Return on equity


Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Pharmaust is 29.14M and its enterprise value is 26.94M. The enterprise value to revenue ratio of PAA is 7.82.

The PAA's stocks Beta value is 0.80 making it 20% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Pharmaust (PAA)

Pharmaust (ASX:PAA) Frequently Asked Questions

1. What is Pharmaust's Stock Symbol?

Pharmaust trades on ASX under the ticker symbol "PAA".

2. What is Pharmaust's stock price today?

One share of PAA stock can currently be purchased for approximately $0.092.

3. How can I contact Pharmaust?

Pharmaust's mailing address is 5/3 Brodie Hall Drive Bentley WA 6102 Australia. The company can be reached via phone at 61 8 9202 6814.

4. What is Pharmaust's official website?

The official website of Pharmaust is

5. Which share registry manages Pharmaust's stock?